03% ophthalmic solution applied to the eyebrows in a randomized, double-blind, vehicle-controlled study.
Methods Subjects (n=20) with mild to moderate eyebrow hypotrichosis enrolled in the study. One group (Bim) applied bimatoprost to each eyebrow daily for 9months, and another applied vehicle nightly to each eyebrow for 5months. Subjects in the latter group were re-randomized to apply 3-deazaneplanocin A bimatoprost (Veh-Bim Group) or vehicle (Veh Group) daily to each eyebrow for 4months. The primary end point was investigator-assessed eyebrow
appearance; secondary end points were subject-reported outcomes.
Results Investigator assessments showed significant improvements from baseline to 6 (p=.002) and 7 (p=.005) months for the eyebrows treated with bimatoprost. p-Values for the Veh-Bim and Veh groups were not significant at any time point. End-of-study subject satisfaction with eyebrow fullness or thickness and darkness or color was greater in the Bim group than in the Veh group. Adverse effects were not observed.
Conclusion Bimatoprost 0.03% ophthalmic solution applied daily for 9months improves the appearance of eyebrows noticeably more than vehicle, without side effects.”
“BACKGROUND: Identification of modifiable psychosocial characteristics related to survival of heart transplant (HTx) candidates is needed to prevent clinical deterioration
and improve prognosis.
METHODS: A multi-site, prospective study was conducted with 318 HTx candidates (18% female, 82% male; 53 I I years of age) newly listed at 17 hospitals in Germany and Austria. Baseline demographic and psychosocial characteristics were assessed by questionnaires. Indicators check details of disease severity (Heart Failure Survival Score, creatinine, cardiac index) and 12-month outcomes (death, high-urgency HTx, elective HTx, de-listing due to deterioration or improvement) were provided by Eurotransplant.
RESULTS: By 12 months, 33 patients
died, 83 received an urgent HTx, 30 underwent an elective HTx, and 9 were de-listed due to clinical deterioration and 17 due to improvement. All measures of disease severity predicted outcomes. Controlling for disease severity, the number of social contacts contributed significantly to outcomes, favoring those Bcl-2 inhibitor who improved. Comparing socially isolated patients (<4 social contacts/month) who also had depression scores in the clinical range (high psychosocial risk group; n = 37) to those with >10 social contacts/month without depression (low psychosocial risk group; n = 47) revealed significant differences in the distribution of outcome frequencies (chi-square = 11.2, df = 4, p < 0.04). The high psychosocial risk group was more likely to have died/deteriorated and less likely to have improved than the low psychosocial risk group.
CONCLUSIONS: Regardless of disease severity, socially isolated HTx candidates who are also depressed may be at increased risk for clinical deterioration and mortality, indicating a need for psychosocial intervention.